219132-76-0

Basic information

• Product Name: N-[4-(4-Methyl-1-piperazinyl)phenyl]-guanidine
• Synonyms: N-[4-(4-Methyl-1-piperazinyl)phenyl]-guanidine;Guanidine, N-[4-(4-Methyl-1-piperazinyl)phenyl]-;2-[4-(4-methylpiperazin-1-yl)phenyl]guanidine
• CAS NO: 219132-76-0
• Molecular Formula: C12H19N5
• Molecular Weight: 233.31276
• Mol File: 219132-76-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 385.2 °C at 760 mmHg
• Flash Point: 186.8 °C
• Appearance: /
• Density: 1.24 g/cm³
• CAS DataBase Reference: N-[4-(4-Methyl-1-piperazinyl)phenyl]-guanidine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(4-Methyl-1-piperazinyl)phenyl]-guanidine(219132-76-0)
• EPA Substance Registry System: N-[4-(4-Methyl-1-piperazinyl)phenyl]-guanidine(219132-76-0)

Safety Data

• Hazardous Substances Data: 219132-76-0(Hazardous Substances Data)

Usage

General Description

N-[4-(4-Methyl-1-piperazinyl)phenyl]-guanidine, also known as MPPG, is a chemical compound with the formula C13H22N4. It is a guanidine derivative and a potent and selective antagonist for the 5-HT3 receptor. MPPG has been used in scientific research to study the effects of serotonin in the central nervous system and to investigate the potential therapeutic applications of 5-HT3 receptor antagonists. It has also been implicated in the modulation of pain perception and has been studied for its potential in the treatment of conditions such as chemotherapy-induced nausea and vomiting, irritable bowel syndrome, and anxiety. Additionally, MPPG may have potential as a tool in the development of novel pharmacological treatments for neurological disorders and psychiatric conditions.

Upstream product

• 1143571-97-4 (Z)-tert-butyl (tert-butoxycarbonylamino)(4-(4-methylpiperazin-1-yl)phenylamino)methylenecarbamate 
• 16153-81-4 4-(4-Methyl-piperazino)-anilin 
• 420-04-2 CYANAMID 

Relevant articles and documents

Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors

CDK4/6 pathway is an attractive target for development of anti-cancer drugs. Herein, we reported the design and synthesis of a series of 4,5-dihydro-1H-pyrazolo [4,3-h]quinazoline derivatives as selective CDK4/6 inhibitors. Applied with the optimizing strategy to the initial scaffold, it is found that compound 13n is able to selectively inhibit CDK4 and CDK6 with IC50 values 0.01 and 0.026 μM, respectively. The compound showed good anti-proliferative activity when tested in a panel of tumor cell lines with CDK4/6 related mechanism of action, the results clearly suggest that compound 13n works much better than Ly2385219 which is a selective CDK4/6 inhibitor. This compound was also found to have favorable pharmacokinetic parameters. Taken together, compound 13n could be selected for further preclinical evaluation.